University of Campania Luigi Vanvitelli
Also known as: A.O.U. dell'Università degli studi della Campania "Luigi Vanvitelli" | Azienda Ospedaliera dei Colli | Chair of cardiology Second University of Naples | Department of Geriatrics and Metabolic Diseases, Second University of Naples, Italy | Department of Psychiatry - University of Campania "Luigi Vanvitelli" | Gaetano Isola, DDS, PhD | Second University Naples | Second University of Naples, Italy; Chair Medical Oncology | Second University of Naples, Italy; Chair Medical Statistics | Second University of Naples, Italy; Chair of Medical Statistics | Second University of Naples Medical School | Second Univesity of Naples | Second Univesity of Naples, Italy | Second Univesity of Naples, Italy; Chair Medical Oncology | Serafino A. Marsico | Unit of Endocrinology and Metabolic Diseases University of Campania Luigi Vanvitelli | università degli studi della campania Luigi Vanvitelli | Università della Campania L Vanvitelli | University of Campania "Luigi Vanvitelli" | University of Campania Luigi Vanvitelli
Highest phase reached
Phase 4
First clinical trial
Jan 1, 1999Last known activity
Dec 31, 2025
Timeline
1990s
- Jan 1, 1991
University of Campania Luigi Vanvitelli— Founded
Drugs by trial phase (110 distinct, 85 trials)
Phase 4 (43 own, 0 via acquisition)
Phase 3 (37 own, 0 via acquisition)
Phase 2 (22 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Other trials (7 own, 0 via acquisition)
Indications
Studied for
- Amyotrophic Lateral Sclerosis
- Angioid Streaks
- Asthma
- Autonomic Nervous System Diseases
- beta-Thalassemia
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Cardiomyopathies
- Choroidal Neovascularization
- Colonic Neoplasms
- Colorectal Neoplasms
- Communicable Diseases
- Coronary Artery Disease
- Coronary Disease
- Cystic Fibrosis
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Diabetic Retinopathy
- Endometrial Neoplasms
- Fallopian Tube Neoplasms
- Fibrosis
- Foot Ulcer
- Healthcare-Associated Pneumonia
- Heart Diseases
- Heart Failure
- Helicobacter Infections
- Hyperlipidemias
- Hyperlipoproteinemias
- Hypersensitivity
- Hypertension
- Hypoglycemia
- Infarction
- Infections
- Intraabdominal Infections
- Ischemia
- Keratosis
- Keratosis, Actinic
- Kidney Diseases
- Kidney Failure, Chronic
- Lung Neoplasms
- Melanoma
- Motor Neuron Disease
- Myocardial Infarction
- Myocardial Ischemia
- Myopia
- Myopia, Degenerative
- Neovascularization, Pathologic
- Nervous System Diseases
- Osteoporosis
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Pneumonia
- Pneumonia, Ventilator-Associated
- Recurrence
- Renal Insufficiency, Chronic
- Retinal Diseases
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Sclerosis
- Small Cell Lung Carcinoma
- Tachycardia
- Takotsubo Cardiomyopathy
- Thalassemia
- Ulcer
- Uterine Cervical Neoplasms
Recent trials (50)
- NCT07176104Lead sponsorN/ADec 31, 2025
- NCT07176104Sponsor investigatorN/ADec 31, 2025
- NCT06778564CollaboratorPhase 3Apr 30, 2025
- NCT06718452Lead sponsorN/AJan 2, 2025
- NCT06718452Sponsor investigatorN/AJan 2, 2025
- NCT06125054CollaboratorPhase 2Dec 31, 2023
- NCT06659016Lead sponsorPhase 4Feb 1, 2023
- NCT06659016Sponsor investigatorPhase 4Feb 1, 2023
- NCT05291156Lead sponsorPhase 2Jul 21, 2022
- NCT05291156Overall official - principal investigatorPhase 2Jul 21, 2022
- NCT05291156Reponsible party - principal investigatorPhase 2Jul 21, 2022
- NCT05223673Overall official - principal investigatorPhase 3Apr 21, 2022
- NCT05287503CollaboratorPhase 2Feb 15, 2022
- NCT05312398Reponsible party - principal investigatorPhase 2Jul 15, 2021
- NCT05312398Lead sponsorPhase 2Jul 15, 2021
Details
- Founded
- Caserta, IT Jan 1, 1991
- Last known activity
- Dec 31, 2025